Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22142006 | 1.00 | GBA1 (0.41) | GBA1KCNH2HRH3ALDH1A1OPRD1 | |
| SCHEMBL22141999 | 1.00 | GBA1 (0.41) | GBA1KCNH2HRH3ALDH1A1OPRD1 | |
| SCHEMBL22142003 | 1.00 | GBA1 (0.41) | GBA1KCNH2HRH3ALDH1A1OPRD1 | |
| SCHEMBL22142028 | 0.81 | CYP2D6 (0.38) | KCNH2OPRD1 | |
| SCHEMBL22142110 | 0.81 | CYP2D6 (0.38) | KCNH2OPRD1 | |
| SCHEMBL22142031 | 0.81 | CYP2D6 (0.38) | KCNH2OPRD1 | |
| SCHEMBL22142248 | 0.80 | GBA1 (0.41) | GBA1KCNH2HRH3ALDH1A1 | |
| SCHEMBL22142842 | 0.80 | GBA1 (0.38) | GBA1KCNH2HRH3ALDH1A1 | |
| SCHEMBL22142241 | 0.80 | GBA1 (0.41) | GBA1KCNH2HRH3ALDH1A1 | |
| SCHEMBL16418015 | 0.80 | HRH3 (0.50) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2020132384-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | GBA1 4629/4885KCNH2 1015/4885HRH3 779/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | GBA1 4629/4885KCNH2 1015/4885HRH3 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.